• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Journal of Pharmaceutical Research

Year: 2026, Volume: 25, Issue: 3, Pages: 202-205

Case Report

Concurrent Methotrexate Induced Bone Marrow Suppression and Diclofenac Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome) in a Patient with Rheumatoid Arthritis: A Case Report

Abstract

Methotrexate and diclofenac are commonly used drugs for the treatment of rheumatoid arthritis. Methotrexate is a disease modifying antirheumatic drug utilized for managing rheumatoid arthritis for long term disease control, while diclofenac is frequently used for symptomatic relief of pain and inflammation. Low dose weekly treatments are generally regarded as safe and effective; however, significant side effects may arise due to dosing mistakes, older age, folate deficiency or accompanying health issues. On the other hand, diclofenac can cause rare but serious adverse hypersensitivity reactions like DRESS syndrome. We describe a 68- year- old man with rheumatoid arthritis who experienced severe leukopenia, thrombocytopenia, mucocutaneous ulcerations, and a secondary bacterial infection after unintentionally taking an extra dose of methotrexate while having discontinued folic acid supplementation for an extended period. Furthermore, the patient had a recent history of diclofenac usage for aggravated joint pain and then presented with a widespread skin rash, eosinophilia, liver involvement and other systemic inflammatory response aligning with DRESS syndrome. The patient was treated with intravenous leucovorin rescue, granulocyte colony- stimulating factor, and broad spectrum antibiotics when methotrexate was stopped right away. With supportive care, a gradual hematologic recovery was accomplished. This instance highlights how crucial it is for patients using methotrexate to receive regular laboratory testing, folic acid therapy and patient education and not to self- medicate.

Keywords: Leucovorin rescue, Rheumatoid arthritis, Bone marrow suppression, Pancytopenia, Methotrexate toxicity, Medication mistake, DRESS syndrome, Diclofenac

References

1. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Annals of the Rheumatic Diseases. 2009; 68 (7). Available from: https://doi.org/10.1136/ard.2008.092668

2. Cronstein BN. Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis. Pharmacological Reviews. 2005; 57 (2). Available from: https://doi.org/10.1124/pr.57.2.3

3. Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate. Cochrane Database of Systematic Reviews. 2013; 2013 (5). Available from: https://doi.org/10.1002/14651858.CD000951.pub2

4. Kremer JM. Toward a better understanding of methotrexate. Arthritis & Rheumatism. 2004; 50 (5). Available from: https://doi.org/10.1002/art.20278

5. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. The Oncologist. 2016; 21 (12). Available from: https://doi.org/10.1634/theoncologist.2015-0164

6. Widemann BC, Adamson PC. Understanding and Managing Methotrexate Nephrotoxicity. The Oncologist. 2006; 11 (6). Available from: https://doi.org/10.1634/theoncologist.11-6-694

7. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. British Journal of Dermatology. 2013; 169 (5). Available from: https://doi.org/10.1111/bjd.12501

Copyright

© 2026 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)

DON'T MISS OUT!

Subscribe now for latest articles and news.